Labcorp price target raised to $275 from $250 at Barclays

Barclays raised the firm’s price target on Labcorp (LH) to $275 from $250 and keeps an Equal Weight rating on the shares as part of a Q2 preview. The diagnostics setup is “relatively neutral,” with biopharma laboratory services updates likely the bigger focus item given the exposure to policy and macro uncertainty, the analyst tells investors in a research note. The firm says that while Labcorp had not seen disruption to biopharma activity levels as of Q1, it takes a more cautious stance given a number of negative biotech funding data points.